EUVIMEDEUVIMED entdecken
Open Access

Ebastine targets HER2/HER3 signaling and cancer stem cell traits to overcome trastuzumab resistance in HER2‑positive breast cancer

Eunsun Jung, Ji Young Kim, Dongmi Ko, Juyeon Seo, Sang Yoon Lee, Daeun Lee, Subeen Kim, Minsu Park, Seongjae Kim, Soeun Park, Kyoungmin Lee, Yong Koo Kang und 3 weitere

International Journal of Molecular Medicine · 2026

DOI: 10.3892/ijmm.2026.5751 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Medicine, 2026. Verfasst von Eunsun Jung und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Korea University College of Medicine, Korea University, Seoul 152‑703, Republic of Kor…. Hauptthemen laut MEDLINE: Neoplastic Stem Cells, Drug Resistance, Neoplasm, Breast Neoplasms, Trastuzumab. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

safety profile. These findings demonstrated that ebastine effectively disrupts key pathways involved in CSC‑like traits and HER2 activity, even under trastuzumab‑resistant conditions. Its multifaceted inhibitory effects support the repositioning of ebastine as a promising therapeutic strategy for treating refractory HER2‑positive breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplastic Stem CellsDrug Resistance, NeoplasmBreast NeoplasmsTrastuzumabErb-b2 Receptor Tyrosine KinasesSignal TransductionReceptor, ErbB-3PiperidinesHumansFemaleAnimalsCell Line, TumorXenograft Model Antitumor AssaysMice, NudeMolecular Docking SimulationMiceApoptosisCell ProliferationMice, Inbred BALB C

Stichwörter der Autor:innen

HER2‑positive breast cancerapoptosiscancer stem celldrug repurposingebastinetrastuzumab resistance

Substanzen

TrastuzumabErb-b2 Receptor Tyrosine KinasesReceptor, ErbB-3PiperidinesERBB2 protein, humanERBB3 protein, human

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Internal Medicine, Korea University College of Medicine, Korea University, Seoul 152‑703, Republic of Korea.

Zitieren

APA

Jung, E., Kim, J. Y., Ko, D., Seo, J., Lee, S. Y., Lee, D., Kim, S., Park, M., Kim, S., Park, S., Lee, K., Kang, Y. K., Nam, K. D., Kim, Y. J., & Seo, J. H. (2026). Ebastine targets HER2/HER3 signaling and cancer stem cell traits to overcome trastuzumab resistance in HER2‑positive breast cancer. International Journal of Molecular Medicine. https://doi.org/10.3892/ijmm.2026.5751

Vancouver

Jung E, Kim JY, Ko D, Seo J, Lee SY, Lee D, et al. Ebastine targets HER2/HER3 signaling and cancer stem cell traits to overcome trastuzumab resistance in HER2‑positive breast cancer. International Journal of Molecular Medicine. 2026. doi:10.3892/ijmm.2026.5751

BibTeX
@article{Jung2026,
  author = {Jung, Eunsun and Kim, Ji Young and Ko, Dongmi and Seo, Juyeon and Lee, Sang Yoon and Lee, Daeun and Kim, Subeen and Park, Minsu and Kim, Seongjae and Park, Soeun and Lee, Kyoungmin and Kang, Yong Koo and Nam, Kee Dal and Kim, Yoon-Jae and Seo, Jae Hong},
  title = {Ebastine targets HER2/HER3 signaling and cancer stem cell traits to overcome trastuzumab resistance in HER2‑positive breast cancer},
  journal = {International Journal of Molecular Medicine},
  year = {2026},
  doi = {10.3892/ijmm.2026.5751}
}
Kostenlos starten →